Kairos Pharma Ltd.

10/23/2025

is pioneering a new approach to focused on overcoming drug resistance.

By developing resistance reversal therapeutics like , Kairos aims to improve the effectiveness of existing therapies and give patients more time.

Read the full interview in Invezz with CEO, John Yu, M.D:

J

10/20/2025

presents on the positive interim efficacy data from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant ( ) at the annual ESMO - European Society for Medical Oncology's 2025 European Congress.

The interim efficacy analysis highlights potential value of combination therapy.

Read the full release here: bit.ly/4oxy716

10/17/2025

This year, more than 313,000 men in the U.S. are expected to be diagnosed with , with over 35,000 deaths projected, according to the American Cancer Society.

is advancing innovative science to transform the future of treatment and improve outcomes for patients facing this disease.

Learn more about how is driving progress: kairospharma.com

10/14/2025

Kairos Pharma’s CEO & Chairman, John Yu, M.D., was featured in a Pharma’s Almanac article on how companies can meaningfully incorporate patient voices into drug development decisions.

Check out the responses from Dr. Yu and additional experts here: https://bit.ly/4pIe7u1

10/09/2025

The 2025 Nobel Prize winners in Physiology or Medicine were honored for discoveries in immune tolerance, highlighting the role of regulatory T cells (Tregs) in cancer’s ability to evade the immune system.

is advancing this frontier with KROS-101, our GITR ligand agonist that expands cytotoxic T cells while inhibiting Tregs to target cancer cells and reverse immune suppression, reprogramming the tumor microenvironment to strengthen the body’s natural anti-cancer defenses.

's commitment to translating this Nobel-recognized science into transformative therapies underscores our dedication to improving outcomes for cancer patients worldwide.

Learn more about the 2025 winners and the discoveries behind regulatory T cells:

The Nobel Prize in Physiology or Medicine 2025 was awarded jointly to Mary E. Brunkow, Frederick J. Ramsdell and Shimon Sakaguchi "for their discoveries concerning peripheral immune tolerance"

10/07/2025

announces it has been selected to present positive safety and efficacy data from its Phase 2 of lead candidate in advanced prostate cancer at ESMO -European Society for Medical Oncology's 2025 European Congress.

The presentation, led by Dr. Neil Bhowmick, President & Chief Scientific Officer, will share encouraging safety and early efficacy findings from an interim analysis of the randomized trial in men with metastatic castration-resistant who had progressed on prior hormone therapies.

Read the full press release here: https://bit.ly/3KKRMvH

10/01/2025

’s CEO & Chairman, John Yu, M.D., was featured in an article from on the keys to making rare disease drug development sustainable.

Check out both Dr. Yu and other experts comments here: https://bit.ly/4pIe7u1

09/30/2025

On the final day of , we’re proud to spotlight the work being done at to advance innovative therapies.

CEO & Chairman, John Yu, M.D., recently joined to share how is advancing research and specifically aimed at tackling , along with upcoming milestones in treating other difficult-to-treat cancers.

Watch the full interview below:

You can find the recording of the KOL event Dr. Yu discusses in this clip here: https://bit.ly/3VInPyx

09/25/2025

: hosted a premier KOL event last week to discuss diverse perspectives on ’s interim efficacy results from a Phase 2 of its lead candidate, , in treating advanced patients.

Check out the full video recording of this event here to learn more: bit.ly/3VInPyx

09/22/2025

’s positive data from our Phase II treatment was recently covered by Arena.

Read their coverage here: https://bit.ly/4gD30OH

Kairos Pharma has reported encouraging interim efficacy data from its Phase II study of ENV105 in individuals with mCRPC.

09/18/2025

's premier KOL event begins at 5 p.m. ET / 2 p.m. PT! Join to hear industry experts discuss 's interim efficacy results from the Phase 2 of its lead candidate, , in treating advanced patients.

Sign-up here: bit.ly/3VInPyx

Join ’s premier KOL event this Thursday, Sept. 18th at 5 p.m. ET / 2 p.m. PT as industry experts discuss diverse perspectives on ’s interim efficacy results from a Phase 2 of its lead candidate, , in treating advanced patients.

Huntsman Cancer Institute, Massachusetts General Hospital, Harvard Medical School

Sign-up for the webcast here: https://bit.ly/3VInPyx

09/18/2025

announces positive efficacy data from its ongoing Phase 2 trial of (carotuximab) in patients with metastatic castration-resistant ( ).

Read the full press release here: bit.ly/46mcrgJ

is hosting a virtual KOL (key opinion leader) event to provide perspectives on this data at 5 p.m. ET / 2 p.m. PT today. Interested participants can sign-up to receive the webcast link here: bit.ly/3VInPyx